Veradigm Newsroom

TD Cowen Maintains Veradigm(MDRX.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsSep 10 07:33 ET

Veradigm (MDRX) Gets a Buy From TD Cowen

TipRanksSep 10 07:17 ET

Veradigm Analyst Ratings

BenzingaMay 28 11:41 ET

Buy Rating Affirmed for Veradigm: Growth Prospects and Market Position Highlighted

TipRanksMay 28 06:20 ET

Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15

MT NewswiresMar 19 10:44 ET

Veradigm Analyst Ratings

BenzingaMar 19 06:04 ET

Veradigm's Challenging Outlook: Hold Rating Justified Amid Revenue Growth, Margin Pressures, and Audit Concerns

TipRanksMar 19 04:41 ET

Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)

TipRanksMar 15 21:55 ET

Veradigm Analyst Ratings

BenzingaJan 19 09:05 ET

RBC Halves Price Target on Veradigm to $11 From $22, Keeps Outperform Rating

MT NewswiresJan 19 08:12 ET

Barclays Starts Allscripts Healthcare Solutions With Equalweight Rating, $11 Price Target

MT NewswiresJan 3 07:41 ET

Barclays Initiates Coverage On Veradigm With Equal-Weight Rating, Announces Price Target of $11

BenzingaJan 3 05:32 ET

Veradigm Analyst Ratings

BenzingaJan 3 05:31 ET

Deutsche Bank Adjusts Veradigm Price Target to $15 From $18, Maintains Buy Rating

MT NewswiresDec 11, 2023 10:25 ET

Stephens & Co. Reiterates Equal-Weight on Veradigm, Maintains $13 Price Target

BenzingaNov 14, 2023 08:23 ET

Veradigm Analyst Ratings

BenzingaNov 14, 2023 08:21 ET

Stephens & Co. Reiterates Equal-Weight on Veradigm, Maintains $13 Price Target

BenzingaOct 10, 2023 10:16 ET

Veradigm Analyst Ratings

BenzingaOct 10, 2023 10:15 ET

Research Alert: CFRA Drops Analytical Coverage Of Veradigm Inc.

MT NewswiresOct 10, 2023 10:15 ET

RBC Capital Reaffirms Their Buy Rating on Veradigm (MDRX)

TipRanksJul 20, 2023 21:46 ET